CHUGAI PHARMACEUTICAL CO., LTD.

Home > Investor Relations > Reports & Downloads > Development Pipeline

Development Pipeline

Oncology

Development code
(Compound number)
Indication
# Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG1273
(RO4368451)
Breast cancer Launched
(13/09)
pertuzumab
Perjeta®
Injection
Roche
Perjeta®
HER2 dimerization inhibitory humanized monoclonal antibody
Breast cancer (adjuvant) # Phase III
Multinational study
Gastric cancer # Phase III
Multinational study
RG435
(RO4876646)
Ovarian cancer # Approved
(13/11)
bevacizumab
Avastin®
Injection
Roche
Avastin®
Anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody
Breast cancer (adjuvant) # Phase III
Multinational study
RG3502
(RO5304020)
Breast cancer Approved
(13/09)
trastuzumab emtansine
Kadcyla®
Injection
Roche
Kadcyla®
Anti-HER2 antibody-drug conjugate (T-DM1)
Gastric cancer # Phase II / III
Multinational study
RG3638
(RO5490258/
PRO143966)
Non-small cell lung cancer Phase III
Multinational study
onartuzumab
 
Injection
Roche Anti-Met humanized monoclonal antibody (MetMAb)
GA101/RG7159
(RO5072759)
Indolent NHL Phase III
Multinational study
obinutuzumab
 
Injection
Roche
 
(Nippon Shinyaku)
Glycoengineered type II anti-CD20 monoclonal antibody
Aggressive NHL Phase III
Multinational study
GC33/RG7686
(GC33/
RO5137382)
Liver cancer Phase II
Multinational study
 
 
Injection
In-house

(Roche)
Anti-Glypican-3 humanized monoclonal antibody
RG340
(Ro09-1978)
Gastric cancer (adjuvant) # Phase II capecitabine
Xeloda®
Oral
Roche
Xeloda®
(Yakult Honsha)
Antimetabolite, 5-FU derivative
AF802/RG7853
(CH5424802/
RO5424802)
Non-small cell lung cancer Filed
(13/10)
alectinib

Oral
In-house

(Roche)
ALK inhibitor
Phase I / II
Overseas
RG7204
(RO5185426)
Melanoma Phase I / II vemurafenib

Oral
Roche
Zelboraf®
BRAF inhibitor
CIF/RG7167
(RO4987655)
Solid tumors Phase I

Oral
In-house

(Roche)
MEK inhibitor
Phase I
Overseas
CKI27/RG7304
(RO5126766)
Solid tumors Phase I

Oral
In-house

(Roche)
Raf and MEK dual inhibitor
Phase I
Overseas
PA799
(CH5132799)
Solid tumors Phase I
Overseas


Oral
In-house PI3K class I inhibitor
RG7414
(RO5490248)
Solid tumors Phase I parsatuzumab

Injection
Roche Anti-EGFL7 humanized monoclonal antibody
RG7321
(GDC-0941)
Solid tumors Phase I pictilisib

Oral
Roche PI3K inhibitor
RG7446
(MPDL3280A)
Solid tumors Phase I

Injection
Roche Engineered anti-PDL1 monoclonal antibody

Bone and Joint Diseases

Development code
(Compound number)
Indication
# Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG484
(Ro200-5450iv)
(Ro200-5450po)
Osteoporosis Launched
(13/08)
ibandronate sodium hydrate
Bonviva®
Injection
Roche
Boniva® (US) / Bonviva® (EU)
(Taisho Pharmaceutical)
Bisphosphonate
Phase III ibandronate sodium hydrate

Oral
NRD101
(NRD101)
Enthesopathy
(Lateral epicondylitis, Patellar tendinitis,
Achilles tendinopathy, Plantar fasciitis) #
Phase III sodium hyaluronate
Suvenyl®
Injection
In-house Sodium hyaluronate

Autoimmune Diseases

Development code
(Compound number)
Indication
# Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
MRA
(MRA-SC)
Rheumatoid arthritis (new formulation: subcutaneous injection) Approved
(13/10)
US
tocilizumab
Actemra® / RoActemra® (EU)
Injection
In-house

(Roche)
Humanized anti-human IL-6 receptor monoclonal antibody
Filed
(12/12)
EU
MRA
(RO4877533)
Giant Cell Arteritis # Phase III
Overseas
tocilizumab
Actemra® / RoActemra® (EU)
Injection
In-house

(Roche)
Humanized anti-human IL-6 receptor monoclonal antibody
Systemic Sclerosis # Phase II
Overseas
SA237
(SA237)
Rheumatoid arthritis Phase I

Injection
In-house Anti-IL-6 receptor humanized monoclonal antibody
RG7415
(PRO155767)
Systemic lupus erythematosus (SLE) Phase I rontalizumab

Injection
Roche Anti-interferon alpha humanized monoclonal antibody

Central Nervous System

Development code
(Compound number)
Indication
# Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG1678
(RO4917838)
Schizophrenia Phase III
Multinational study
bitopertin

Oral
Roche Glycine reuptake inhibitor
RG7090
(RO4917523)
Major depressive disorder Phase II
Multinational study


Oral
Roche mGluR5 antagonist
RG1450
(RO4909832)
Alzheimer’s disease Phase I gantenerumab

Injection
Roche / MorphoSys Anti-amyloid-beta human monoclonal antibody
RG1577
(RO4602522)
Alzheimer’s disease Phase I

Oral
Roche MAO-B inhibitor

Respiratory Diseases

Development code
(Compound number)
Indication
# Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG3637
(RO5490255)
Asthma Phase III
Multinational study
lebrikizumab
 
Injection
Roche Anti-IL-13 humanized monoclonal antibody

Others

Development code
(Compound number)
Indication
# Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
CIM331
(CIM331)
Atopic dermatitis Phase II*
Multinational study
 
 
Injection
In-house Anti-IL-31 receptor humanized monoclonal antibody
ACE910
(ACE910)
Hemophilia A Phase I / II  
 
Injection
In-house Anti-factor IXa × anti-factor X humanized bispecific antibody
RG7652 Hyperlipidemia Phase I
Overseas
 
 
Injection
Roche Anti-PCSK9 human monoclonal antibody
URC102
(URC102)
Gout Phase I
Overseas
 
 
Oral
In-house /
JW Pharmaceuticals
URAT1 inhibitor

* Multinational study managed by Chugai

To view PDF files,
you will need Adobe® Reader® which is available as a free download.